Listed

NextCure, Inc.: Form 10-K for the period ended Dec 31, 2021

Filed with the SEC on Mar 3, 2022 and accepted by EDGAR at Mar 3, 2022, 17:01 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development12 months2021-01-01 to 2021-12-31$50.2mus-gaap:ResearchAndDevelopmentExpense
Operating income12 months2021-01-01 to 2021-12-31−$70.8mus-gaap:OperatingIncomeLoss
Net income12 months2021-01-01 to 2021-12-31−$69.4mus-gaap:NetIncomeLoss
Diluted EPS12 months2021-01-01 to 2021-12-31−$2.51us-gaap:EarningsPerShareDiluted
Basic EPS12 months2021-01-01 to 2021-12-31−$2.51us-gaap:EarningsPerShareBasic
Diluted shares (weighted)12 months2021-01-01 to 2021-12-3127,615,977 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow12 months2021-01-01 to 2021-12-31−$57.2mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2021-01-01 to 2021-12-31$2.4mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2021-12-31$12.3mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2021-12-31$227.8mus-gaap:AssetsCurrent
Total assetsAt period end2021-12-31$242.4mus-gaap:Assets
Current liabilitiesAt period end2021-12-31$6.6mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2021-12-31$9.0mus-gaap:Liabilities
Long-term debtAt period end2021-12-31$0us-gaap:LongTermDebt
Shareholders' equityAt period end2021-12-31$233.4mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001558370-22-002824. Last ingested by Listed: Oct 30, 2026, 08:01 ET. Listed shows no prices and gives no investment advice.